BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI)
CUSIP: 09075P204
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 21,847,524
- Total 13F shares
- 3,538,520
- Share change
- +1,195,942
- Total reported value
- $5,667,324
- Price per share
- $1.60
- Number of holders
- 42
- Value change
- +$1,743,166
- Number of buys
- 23
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 09075P204?
CUSIP 09075P204 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09075P204:
Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Rashmi Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,554,945
|
$187,267,747 | — | 03 Apr 2023 | |
| Vipin Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,554,945
|
$187,267,747 | — | 03 Apr 2023 | |
| Indu R. Gupta |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,550,396
|
$187,168,169 | — | 03 Apr 2023 | |
| Tarun K. Gupta |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,550,396
|
$187,168,169 | — | 03 Apr 2023 | |
| Suganthi Balasubramanian |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,750
|
$187,110,248 | — | 03 Apr 2023 | |
| Anita Jain |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,300
|
$187,100,398 | — | 03 Apr 2023 | |
| Diwakar Jain |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,300
|
$187,100,398 | — | 03 Apr 2023 | |
| Krishnan Nandabalan |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
8,840,750
mixed-class rows
|
$187,088,358 | — | 06 Apr 2023 | |
| Akrati Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Alka Sood |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Anesha Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Bina Jatin Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| BioXcel Holdings, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 25 Jun 2021 | |
| BioXcel LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 25 Jun 2021 | |
| Jatin Markand Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Krunal Dilip Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Marshal D. Gibson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Michael James Aiello |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Pardeep Kumar Sood |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
Millennium Management LLC |
8.4%
|
1,835,192
|
$3,762,144 | +$1,654,635 | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
4.7%
|
1,028,053
|
$2,631,816 | — | 30 Sep 2025 | |
| OAKTREE CAPITAL MANAGEMENT LP |
13F
|
Company |
1.1%
|
241,188
|
$617,443 | — | 30 Sep 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
288,131
|
$564,737 | -$9,229,922 | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.91%
|
198,600
|
$508,416 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.88%
|
192,125
|
$491,840 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.57%
|
125,240
|
$320,622 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.52%
|
113,364
|
$290,212 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.39%
|
84,282
|
$215,762 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.24%
|
52,718
|
$134,958 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.2%
|
43,542
|
$111,468 | — | 30 Sep 2025 | |
| Oaktree Fund Advisors, LLC |
13F
|
Company |
0.2%
|
42,913
|
$109,857 | — | 30 Sep 2025 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0.16%
|
36,000
|
$97,200 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.17%
|
37,733
|
$96,597 | — | 30 Sep 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.16%
|
35,000
|
$89,600 | — | 30 Sep 2025 | |
| FOUNDATIONS INVESTMENT ADVISORS, LLC |
13F
|
Company |
0.14%
|
29,549
|
$75,645 | — | 30 Sep 2025 | |
| SLT Holdings LLC |
13F
|
Company |
0.14%
|
29,500
|
$75,520 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.07%
|
15,083
|
$61,066 | — | 30 Sep 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.07%
|
16,316
|
$41,769 | — | 30 Sep 2025 | |
| Oaktree Capital Group Holdings GP, LLC |
13D/G
|
Oaktree Capital Holdings, LLC |
2.7%
|
170,230
|
$28,939 | -$434,154 | 31 Mar 2025 | |
| DIVERSIFY WEALTH MANAGEMENT, LLC |
13F
|
Company |
0.07%
|
15,000
|
$28,500 | — | 30 Sep 2025 | |
| Qatar Investment Authority |
13D/G
|
— |
0.6%
|
156,066
|
$26,531 | -$436,562 | 31 Dec 2025 | |
| Matthew T. Wiley |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
28,386
mixed-class rows
|
$20,056 | — | 17 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
6,881
|
$17,615 | — | 30 Sep 2025 | |
| IFP Advisors, Inc |
13F
|
Company |
0.02%
|
4,370
|
$11,187 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
3,933
|
$10,068 | — | 30 Sep 2025 | |
| Vincent O'Neill |
3/4/5
|
Executive Vice President, Chief of Product Development and Medical Officer |
—
mixed-class rows
|
24,438
mixed-class rows
|
$7,975 | — | 14 Dec 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.01%
|
2,249
|
$5,757 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
1,641
|
$4,201 | — | 30 Sep 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0.01%
|
1,331
|
$3,408 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
355
|
$909 | — | 30 Sep 2025 |
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q4 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.